Silence Therapeutics (SLN) Short-term Investments (2020 - 2026)

Silence Therapeutics (SLN) has 5 years of Short-term Investments data on file, last reported at $64.4 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments fell 10.09% year-over-year to $64.4 million; the trailing twelve-month figure through Mar 2026 stood at $64.4 million (down 10.09% YoY), and the FY2025 full-year result was $73.8 million, up 14.05% from the prior year.
• Short-term Investments declined to $64.4 million in Q1 2026, from $73.8 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $73.8 million in Q4 2025 to a low of $20.2 million in Q3 2025.
• A 4-year average of $57.7 million and a median of $64.7 million in 2024 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments surged 75.11% in 2024 and decreased 10.09% in 2026, its largest moves.
• Tracing SLN's Short-term Investments over 4 years: stood at $37.0 million in 2023, then surged by 75.11% to $64.7 million in 2024, then rose by 14.05% to $73.8 million in 2025, then dropped by 12.75% to $64.4 million in 2026.
• Business Quant data shows SLN's Short-term Investments at $64.4 million in Q1 2026, $73.8 million in Q4 2025, and $20.2 million in Q3 2025.